ArticleInfluenza and other respiratory viruses2019
Associations between common respiratory viruses and invasive group A streptococcal infection: A time-series analysis.
Article in Influenza and other respiratory viruses, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed.
- Streptococcus pyogenes Colonization in Children Aged 24-59 Months in the Gambia: Impact of Live Attenuated Influenza Vaccine and Associated Serological Responses.The Journal of infectious diseases · 2023Trial
- Promoting expertise knowledge sharing in paediatric virology: An update (Review).Experimental and therapeutic medicine · 2026Review
- Epidemiological trends of invasive Streptococcus pyogenes infections in Catalonia, 2022-2024: a two-year analysis.Infection · 2026Article
- Invasive group A streptococcal infections requiring paediatric intensive care in children and adolescents: a nationwide retrospective cohort study in Austria.European journal of pediatrics · 2026Observational
- Clinical characterization of anFrontiers in cellular and infection microbiology · 2026Article
- Severe Group A Streptococcus Infection among Children, France, 2022-2024.Emerging infectious diseases · 2025Article
- Wastewater Surveillance for Group APathogens (Basel, Switzerland) · 2025Article
- Risk factors for invasive group A streptococcal infection in children aged 6 months to 5 years: a case-control study, the Netherlands, February-May 2023.Epidemiology and infection · 2025Article
- A Rapid Molecular Detection Tool for Toxigenic M1UK Streptococcus pyogenes.The Journal of infectious diseases · 2025Article
- Attribution of invasive group A streptococcal infections (iGAS) to predisposing viral infections, the Netherlands, 2010 to 2023.Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin · 2024Article
- Group A Streptococcus infections in children and adolescents in the post-COVID-19 era: a regional Italian survey.Italian journal of pediatrics · 2024Article
- Article
- Group A Streptococcal Infections in Pediatric Age: Updates about a Re-Emerging Pathogen.Pathogens (Basel, Switzerland) · 2024Review
- Clinical and molecular epidemiological features of critically ill patients with invasive group A Streptococcus infections: a Belgian multicenter case-series.Annals of intensive care · 2024Article
- Invasive group A streptococcal infections requiring admission to ICU: a nationwide, multicenter, retrospective study (ISTRE study).Critical care (London, England) · 2024Article
- The ongoing Streptococcus pyogenes (Group A Streptococcus) outbreak in London, United Kingdom, in December 2022: a molecular epidemiology study.Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases · 2023Article
- Increase in invasive group A streptococcal infections in Milan, Italy: a genomic and clinical characterization.Frontiers in microbiology · 2023Article
- The dynamics of scarlet fever in The Netherlands, 1906-1920: a historical analysis.Royal Society open science · 2022Article
- Increasing Incidence of Invasive Group A Streptococcus Disease, Idaho, USA, 2008-2019.Emerging infectious diseases · 2022Article
- Immunotherapy targeting the Streptococcus pyogenes M protein or streptolysin O to treat or prevent influenza A superinfection.PloS one · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundInvasive infections by group A Streptococcus (iGAS, Streptococcus pyogenes) have a winter seasonality which largely coincides with the season for influenza and other respiratory viruses. Influenza superinfections with GAS have been described to occur regularly and to show a severe clinical picture with high mortality. We aimed to study the extent to which influenza A and B viruses (IAV and IBV), respiratory syncytial virus (RSV) and rhinovirus circulation contribute to iGAS incidence and severity.
methodsTime-series regression models were built to explore the temporal associations between weekly laboratory counts of IAV, IBV, RSV and rhinovirus as independent variables and weekly counts of GAS disease notifications or laboratory GAS cultures as dependent variables.
resultsThe weekly number of IAV detections showed a significant temporal association with the number of notifications of streptococcal toxic shock syndrome (STSS), a severe complication of iGAS. Depending on the season, up to 40% of all notified STSS cases was attributable to IAV circulation. Besides STSS, none of the other iGAS manifestations were associated with a respiratory virus.
conclusionsOur study found an ecological temporal association between IAV and STSS, the most severe complication of iGAS. Future studies are needed to confirm this association and assess the possible preventability of STSS by influenza vaccination, especially in the age group 60 years and older.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.